‘FTC Gets Into the ‘Natural’ Game — But Does it Advance the Ball?’, by Ivan Wasserman, New Hope Network, April 2016.
‘Pure Powdered Caffeine: Stakeholders Take Measure of FDA’s Warning Label,’ contribution by Rend Al-Mondhiry, FDLI’s Food and Drug Policy Forum, February 2016.
‘Chapter 33: Dietary Supplements and Homeopathic Products,’ (Update) Fundamentals of Regulatory Affairs (9th Edition), by Ashish Talati and Abhishek Gurnani, Regulatory Affairs Professional Society, 2015. 395-418.
Teva v. Sandoz: The New Standard of Review in Claim Construction, by J. Peter Paredes, Lexology, January 31, 2015.
Promega v. Life Technologies: A Higher Enablement Standard for “Comprising” Not Within the Preamble of the Claim, by J. Peter Paredes, Lexology, January 16 2015.
‘Phase III Biosimilar Clinical Trial & Infringement Threat Does Not Create Justiciable Case or Controversy: Biosimilars Will Require the Patent Dance,’ by Peter Paredes, Lexology, December 15 2014.
‘FeSSIFFaSSIF Dissolution: If You Understand What is Written Above You Should Read This Article’ by J. Peter Paredes, Lexology, December 8, 2014.
‘Bayer, FTC Clash Over Advertising Claims,’ by Abhishek Gurnani, Natural Products Insider, November/December 2014.
In its coverage of the leadership shakeup at FDA and the appointment of a new commissioner, NutraIngredients turned to Ivan Wasserman for comment.
see all news >